Navigation Links
Halozyme Therapeutics to Present at Upcoming Investor Conferences
Date:9/10/2008

ical therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact

Robert H. Uhl Senior Director, Investor Relations

(858) 704-8264

ruhl@halozyme.com

Media Contacts

Karen Sparks / Joleen Schultz

Mentus

(858) 455-5500, x275/x215

karen@mentus.com

jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
4. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
5. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
6. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
9. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
10. Halozyme Therapeutics Amends Stockholder Rights Plan
11. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Report Details ... highest potential revenues Do you want to find ... you revenue predictions for those biological drugs from ... you find financial data, R&D trends, opportunities and ... sales forecasts to 2024 at overall world market, ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... 30, 2014 Fast, semi-automatic ... chemistry in documents ChemAxon , ... consulting services for life science research, launches ChemCurator, ... Markush structures from documents. Markush structures ... however generating and understanding Markush structures is a ...
(Date:9/30/2014)... Sept. 30, 2014 BioHealth Innovation, Inc. ... market-relevant biohealth innovations and increasing access to early-stage funding ... that venture capitalist, Tania Fernandez , Ph.D., has ... Fernandez will be a member of the management team ... up to $50 million in seed and early-stage equity ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... VIENNA, Va., Sept. 16 CEL-SCI Corporation ... vaccines and therapeutics for the prevention and treatment of infectious ... U.S. Food and Drug Administration (FDA) has indicated that the ... the effect of its investigational LEAPS-H1N1 treatment on the white ...
... Sept. 16 Perceptive Informatics, a leading eClinical solutions ... PRXL ), today announced that it has ... osteoarthritis clinical trials through an alliance with Optasia Medical, ... supplement its existing medical imaging technology to improve the ...
... ... and Reduce Risk of False Positives/Negatives , ... Rochester, NY (PRWEB) September 16, 2009 -- iCardiac Technologies, Inc., ... a top 15 pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. ...
Cached Biology Technology:CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 2CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 3CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 4Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities Through Alliance with Optasia 2Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities Through Alliance with Optasia 3Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities Through Alliance with Optasia 4Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
(Date:9/30/2014)... --- Do we think of nature as something that we ... need to "preserve?" Or do we think of ourselves as ... of nature, but what about a house? , The ... also reflected in our actions, our speech and in cultural ... the University of Washington, the American Indian Center of Chicago ...
(Date:9/30/2014)... LA JOLLAJoseph Ecker, a Salk professor and Howard ... staff scientist, have been named recipients in the ... of Health (NIH) through the BRAIN (Brain Research ... in neuroscience. The grant, announced September 30, provides ... Salk scientists over three years. , The BRAIN ...
(Date:9/30/2014)... . FRANKFURT. Truffles, ... the world. Because they grow underground, people use trained dogs ... truffles is not only of interest to gourmets. A group ... Goethe University Frankfurt have discovered that the smell of white ... inside truffle fruiting bodies. , White truffles from the Piedmont ...
Breaking Biology News(10 mins):The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2
... created a synthetic protein that, when activated by ultraviolet light, ... arthritis and other serious medical disorders can be detected. ... imaging technology and may someday serve as a way to ... disease have been found. In a study published in the ...
... be changed by a restaurant,s choice of music and lighting, ... a new study., "When we did a makeover of a ... diners to eat 175 fewer calories and enjoy it more," ... and director of Cornell University,s Food and Brand Lab. ...
... Conn., Aug. 29, 2012 /PRNewswire-iReach/ -- The biobanking market presents ... drug and treatment development for specific diseases. The global ... is projected to increase by 30% between 2010 and 2015, ... sector biobanks will experience the greatest increase with growth of ...
Cached Biology News:Collagen-seeking synthetic protein could lead doctors to tumor locations 2Collagen-seeking synthetic protein could lead doctors to tumor locations 3Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 2Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 3
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Request Info...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Biology Products: